Before you spark up, speak up.
The post 4/20 Is for the Party — The Days Before Are for the Fight appeared first on NORML.
Tag: Midwest
-
Missouri marijuana sales holding steady in 2025
The relatively young Missouri marijuana market – medical sales launched in 2020 and recreational three years later – appears to be holding steady thus far in 2025, even as some of its more mature state counterparts have seen sales plunge.
The midwestern cannabis market in March sold $130.8 million worth of marijuana, including $115.7 million on the adult-use side and another $15.1 million in medical products, according to statistics from the state Department of Health & Senior Services.
That’s the best month of the year thus far, and almost matches December’s holiday sales peak of $130.9 million. Sales dipped in January to $122.8 million and again in February to $116.2 million, before rebounding somewhat in March.
Sales were also up year-over-year from $124.7 a year ago in March, when the state sold $108.6 million in recreational cannabis and $16 million in medical marijuana.
But the market has also diverged – as most state cannabis markets have over time – with medical sliding downward and recreational gaining steam.
Medical sales peaked in December 2022, just two months before the adult-use market launched, with $40.2 million in sales. Since then, the medical marijuana industry has seen its market share plummet, as recreational has blossomed from $93.4 million in just its second month to a steady nine-figure sales report each month.
The last time recreational sales were below $100 million was February 2024, when recreational dispensaries sold $98.3 million and medical dispensaries sold $15 million.
Still, the medical market seems to have stabilized at around $14 million to $15 million in sales per month, a level that it’s been at for the past 12 months. The lowest medical sales month was February this year, when medical patients bought just $13.7 million worth of goods.
Total marijuana sales all-time as of March topped $3.7 billion.
The post Missouri marijuana sales holding steady in 2025 appeared first on Green Market Report.
-
Campus Martius named best public square for 3rd straight year by USA Today’s 10Best Readers’ Choice
Campus Martius Park has been named the top public square in the United States by USA Today’s 10Best Readers’ Choice Awards for the third straight year.
The park was nominated by a team of leading experts and then voted on by the public. The Detroit Riverfront has also been named the best riverfront by USA Today’s 10Best Readers’ Choice Awards.
This win is a reflection of what makes Detroit so special, David Cowan, the chief public spaces officer at the Downtown Detroit Partnership, said in a statement. Campus Martius Park isnt just a square its the soul of the city. From everyday moments to major national events, were proud to keep redefining how public spaces can inspire and connect. Thanks to our amazing partners and everyone who brings this place to life year-round.
Every year, Campus Maritus welcomes more than 4.5 million visitors with over 1,200 free, year-round activities, concerts, festivals and more.
Last year, it welcomed a record-breaking 775,000 people for the NFL Draft.
-
Report: Canadian cannabis market growth slows to 4% in first quarter
Canada’s recreational cannabis market grew just 4% year-over-year in the first quarter of 2025, continuing a trend of decelerating growth from previous years, according to a new industry report.
The analysis from Zuanic & Associates, which examined retail data from Hifyre, shows the market growing at a much slower pace versus the mid-teens growth seen in 2022 and 2023.
Despite ongoing industry consolidation efforts, the cannabis market appears to be becoming more fragmented. The top three companies held 27% market share in the first quarter of 2025, down from around 31% in the same quarter last year, the report found.
Several midsized producers posted strong growth despite the overall market slowdown. Companies with double-digit sales increases include:
Auxly (+32%)
Cannara Biotech (+37%)
Canopy Growth (+28%)
Weed Me (+30%)
Rubicon Organics (+30%)Meanwhile, larger players, including Tilray, Village Farms International and Decibel, experienced double-digit declines in their domestic market share. According to the report, that likely reflects strategic shifts rather than competitive failures.
“For at least the first two, the share loss relates to an increased focus on sustainable sales growth,” the report noted, adding that these companies are shifting “away from deep discounts and the value end of the market.”
The analysis also pointed to format shifts in Canadian consumer preferences. Flower declined from 38% of sales in the first quarter of 2024 to 36% in the first quarter of 2025, while pre-rolls grew from 30% to 32% and vapes from 17% to 18%.
“Compared with the larger U.S. market, vape and edibles are underindexed in Canada, while pre-rolls are overindexed (flower is only slightly underindexed),” Pablo Zuanic, the report’s author, wrote.
Segment leadership shows varying degrees of market concentration. In vape products, the top five companies control 57% of the market, while in flower they hold 49% and in pre-rolls just 34%.
Retail flower prices have largely stabilized, averaging C$5.09 per gram in the quarter compared to C$4.89 a year earlier. However, pricing strategies vary by company, with premium producers like Cannara (C$8.24 per gram), Rubicon (C$8.30) and Aurora (C$7.68) commanding substantially higher price points than the category average, Zuanic said.
Organigram, including its freshly-acquired Motif Labs, maintained its market leadership with 11.6% share, while Tilray dropped nearly 2 percentage points year-over-year to 9.1% and Village Farms fell 1.8 points to 6.2%.
The report suggests that export opportunities may be becoming more important for Canadian producers, noting that “the pull of the export markets is also impacting domestic market share performance and operator economics,” as exports have helped stabilize domestic pricing.
Zuanic found that despite recreational legalization being in place for over six years, Canada’s cannabis market remains underdeveloped versus many U.S. states on a per capita basis. The report estimates Canadian recreational per capita spending at approximately $100, significantly lower than states like Michigan (>$300) and Colorado (>$200).
The post Report: Canadian cannabis market growth slows to 4% in first quarter appeared first on Green Market Report.
-
‘Stoner stereotype’ not enough for cannabis marketing
Cannabis marketing isn’t just about buying ad space on Weedmaps or Leafly anymore. But the options might not be obvious to everyone – and how you advertise matters as much as where, according to one marketing expert.
Today there are a number of avenues available to marijuana businesses trying to expand their reach with customers, according to Karen Cuce, vice president of strategy at Pennsylvania-based Brkthru.
“There are a vast array of options in terms of what cannabis companies can do” to broaden their consumer base and reach new customers, Cuce said. “That can be streaming television, it can be through websites and apps – specifically banner ads, online video or the videos that play before, during, or after a piece of video-based content that the consumer’s watching. Streaming music, streaming audio, podcasts, these are all channels with which the cannabis user is actually spending disproportionately more time than the average U.S. citizen. They are vastly and deeply digitally connected.”
Cuce said her firm focuses primarily on paid media options for cannabis clients, which rules out many of the bigger social media platforms simply because they won’t accept paid ads from marijuana businesses. But at least one – X, formerly known as Twitter – has rolled back such restrictions, Cuce noted.
At the same time, she said, it’s never a good idea to put all your eggs in the same basket when it comes to a marketing strategy. A better plan, she said, is to diversify.
“We can take (cannabis companies’) organic content and seamlessly lift it to run it across, and here’s what I’d recommend, definitely display because that’s going to be a very efficient means to extend reach and really stretch their budget,” Cuce said. “Essentially we’re using very simple imagery as well as a headline, blending it in with the native environment, the publisher on which the ad appears. It’s essentially sponsored content.”
“Both of those channels, as well as online video, have been a really effective trifecta for our cannabis businesses,” Cuce said. “Those are all highly adaptable channels. We can use a number of different targeting approaches.”
A few other pointers Cuce suggested that cannabis companies keep in mind:
Don’t rely on “stoner stereotypes.” Cuce said marketing research has found that modern-day cannabis consumers are diverse, cause-driven, value-driven and often highly successful professionals. “Quite frankly, it’s not just a bunch of people, stereotypically speaking, sitting around eating pizza and potato chips while they’re playing video games. It’s so much more,” Cuce said.
Advertise sales and deals for holidays like 4/20, which can be a great lure for budget-conscious customers. “We know that discounts can be motivating, they can certainly be a hook,” Cuce said.
If a cannabis company has a limited marketing budget, skip marijuana-focused websites like Weedmaps and Leafly in favor of advertising channels that will reach broader “canna-curious” audiences, instead of only those that are already loyal customers. “It is absolutely critical, especially as we see so many cannabis brands really stepping up and owning the space,” Cuce said.The post ‘Stoner stereotype’ not enough for cannabis marketing appeared first on Green Market Report.
-
Arizona marijuana market continues downward trend in February
Arizona cannabis sales stats are down for the second straight year in a row, and have taken enough of a dip that the Arizona Mirror described medical marijuana sales as “cratering” and recreational sales as “softening.”
According to sales figures from the state Department of Revenue, annual sales are down about 10% to $1.3 billion after three years of hitting at least $1.4 billion, according to analysis by the Mirror. And the downturn appears to have no end in sight.
In February, the most recent month for which sales numbers are available, recreational and medical sales combined were just $96.3 million, down almost 15% year-over-year from $113 million. The most recent February numbers included $80.1 million in recreational sales and another $15.6 million in medical, with both figures down year-over-year, from $89.4 million and $23.6 million, respectively.
Last year recreational marijuana sales were down by almost $43 million from 2023, the Mirror reported, while medical sales fell by $114 million between 2023 and 2024.
The medical side of the industry in particular is “a shadow of what it was” just four years ago, the Mirror reported, with sales reaching just a third of what they used to be. Last year, total medical sales hit just $243 million, down from $733 million in 2021.
The recreational market has continued to eclipse the medical side after launching in 2021, the Mirror noted, and comprised 81% of all cannabis sales last year, up from 66% in 2022.
The post Arizona marijuana market continues downward trend in February appeared first on Green Market Report.
-
Missouri revokes 25 cannabis licenses in social equity program crackdown
Missouri cannabis regulators revoked 25 more microbusiness licenses after concluding the operations wouldn’t be genuinely controlled by the disadvantaged entrepreneurs the program was designed to help, the Missouri Independent reported.
The action brings to 34 the number of licenses canceled by the state since the social equity program launched in 2023, representing more than a third of the 96 permits issued through the lottery system, according to a news release from the Missouri Division of Cannabis Regulation on Monday.
The microbusiness program was created to provide cannabis business opportunities for individuals who might otherwise lack access to the industry. However, regulators found evidence that well-connected investors and consultants were recruiting eligible individuals to apply but then arranging deals that limited their control and profits.
“It is not sustainable to keep going through rounds of license issuance and then having to do rounds of revocations,” Amy Moore, director of the state’s cannabis regulatory division, said at a February town hall meeting, according to the Independent. “We’re never going to get this market fully built out.”
The Independent, which has investigated the program for more than a year, reports that Arizona-based cannabis investor Michael Halow is connected to 22 of the revoked licenses, including 16 canceled Monday. Halow reportedly was associated with more than 700 of the approximately 3,600 applications submitted since the program began.
In an email to the outlet, Halow disputed the state’s decision and plans to appeal. He defended his company’s approach, saying they help “people without generational wealth or experience as an entrepreneur” who open “businesses in neighborhoods in need of jobs and economic opportunity.”
Four licenses connected to cannabis consultants David Brodsky and Scott Wootton were also revoked Monday. Regulators cited “false or misleading information” in their agreements that effectively transferred “ownership and operational control to another entity,” according to division documents referenced by the Independent. Brodsky and Wootton declined to comment to the outlet.
The division announced new proposed rules in December aimed at preventing what it called “predatory arrangements in microbusiness licensing.” The state is currently reviewing public comments on these draft regulations before deciding when to submit finalized rules to the Missouri Secretary of State.
The post Missouri revokes 25 cannabis licenses in social equity program crackdown appeared first on Green Market Report.
-
NORML Op-Ed: Marijuana Legalization Advocates Are the Majority. It’s Time to Act Like It
Regardless of whether you live in a red or blue state, or in a jurisdiction where cannabis is legal or illicit, it’s time for legalization advocates to stand up and assert themselves.The post NORML Op-Ed: Marijuana Legalization Advocates Are the Majority. It’s Time to Act Like It appeared first on NORML.
-
Psyence BioMed invests $500,000 more into PsyLabs, locks down Ibogaine supply deal
Psyence Biomedical (NASDAQ: PBM) invested an additional $500,000 in PsyLabs, deepening its relationship with the psychedelic ingredients producer while securing exclusive access to pharmaceutical-grade ibogaine.
The cash infusion builds on Psyence’s initial partnership from September 2024, when it acquired an 11.13% equity stake in PsyLabs and locked down exclusive rights to nature-derived psilocybin for clinical trials.
The new agreement gives Psyence first dibs on worldwide supply of pharmaceutical-grade ibogaine, a psychoactive substance from the Tabernanthe iboga plant being eyed for addiction treatment.
“We’re thrilled to strengthen our partnership with PsyLabs through both our financial investment and this opportunity to acquire exclusive ibogaine supply rights,” CEO Dr. Neil Maresky said in a statement. “Ibogaine holds significant potential as part of a new wave of therapeutics targeting some of the most challenging conditions in mental health.”
Psyence is betting big on nature-derived compounds rather than synthetic alternatives, aiming to build what it calls a “vertically integrated, multi-asset psychedelics biotech platform.” The company plans to evaluate ibogaine specifically for substance use disorders, including alcohol addiction.
Tony Budden, PsyLabs’ chief executive, said the expanded collaboration creates “a powerful platform to explore the full potential of ibogaine and psilocybin in addressing addiction and mental health disorders.”
PsyLabs operates from an ISO 22000-certified facility with federal licenses to handle various psychedelic compounds. The company has already shipped psilocybin products to Canada, the U.K., Portugal and Slovenia.
The deal remains subject to finalizing terms and regulatory approvals.
While touting ibogaine’s potential to “interrupt” addiction, Psyence included the usual disclaimers that regulatory authorities haven’t evaluated claims about psychedelic compounds and that “vigorous scientific research and clinical trials are needed.” The company acknowledges it hasn’t yet conducted clinical trials for its proposed treatments.
The post Psyence BioMed invests $500,000 more into PsyLabs, locks down Ibogaine supply deal appeared first on Green Market Report.
-
Grown Rogue posts strong early results from ABCO Garden State
Grown Rogue International Inc. (CSE: GRIN) (OTC: GRUSF) announced that its New Jersey cannabis cultivation affiliate generated $1.8 million in preliminary first-quarter revenue with gross margins between 55% and 60%, showing some early success in the Garden State market.
The Oregon-based craft cannabis company provided some details on both the performance and financial structuring of its New Jersey operation, ABCO Garden State, LLC.
According to the company, ABCO has achieved cultivation yields exceeding 60 grams of flower per square foot of bench space and has penetrated more than half of New Jersey’s dispensaries with its flower and pre-roll products.
“I’m excited by the initial progress we have seen in New Jersey across cultivation, post-harvest, and sales,” CEO Obie Strickler said in a statement. “We are seeing strong cultivation yields, greater than 60g of flower per square foot of bench space with preliminary gross margin between 55-60%.”
The company reported an average selling price exceeding $2,500 per pound for whole flower and pre-roll products during the first quarter. Strickler noted that ABCO products are seeing “accelerating re-order trends, providing some early validation with respect to our quality, value, and brand strength.”
Grown Rogue currently owns 44% of ABCO but plans to exercise its rights to convert to 70% ownership in fall 2026, the earliest opportunity allowed under New Jersey regulations. The company has structured its investment primarily through senior secured promissory notes that require repayment before any profit distributions, with a March 31 balance of $8.2 million including accrued interest.
“The majority of the capital Grown Rogue has deployed in ABCO has been structured through secured loans,” CFO Andrew Marchington said in the news release. “The repayment of these notes are structured to be paid as a first priority before the distribution of any profits to ABCO partners. We believe this is a preferred deal structure for Grown Rogue shareholders despite its complex impact on our financial statements.”
ABCO is planning some big expansion, with construction of Phase II scheduled to begin in the second quarter. That’ll double steady-state production from the current 500-600 pounds per month to 1,000-1,200 pounds monthly, it said, with full capacity expected by early 2026.
Due to accounting rules, Grown Rogue doesn’t anticipate being able to consolidate ABCO’s financial results until it obtains 70% ownership. Instead, the company said it will provide pro forma disclosure regarding ABCO operations to give investors appropriate transparency.
The post Grown Rogue posts strong early results from ABCO Garden State appeared first on Green Market Report.